Neurological

FDA's query for additional information includes requests for additional analysis of clinical data and proposes certain labeling modifications.

These are the companies in the private sector that medtech analysts have called attention to in 2020.

In March, NeuroMetrix and its CEO agreed to pay nearly $4 million to FTC for the refunds and the company agreed to stop making the allegedly deceptive claims about the pain relief device.

The Marlborough, MA-based company has received CE mark for the fourth generation Vercise Genus Deep Brain Stimulation System.

FDA approved Medtronic's rechargeable device to deliver sacral neuromodulation therapy for the treatment of overactive bladder, fecal incontinence, and non-obstructive urinary retention.

The Irvine, CA-based company said at two years, about 80% of patients in the ARTISAN-SNM study achieved greater than or equal to 75% improvement, with 37% being completely dry.

The Abbott Park, IL-based company said the approval allows patients living with neurological conditions the ability to manage therapy directly from their personal smartphone.